Related Experiment Videos
Beta-sheet breakers for Alzheimer's disease therapy
1Protein Misfolding Disorders Laboratory, Department of Neurology, University of Texas Medical Branch, Galveston, TX, USA.
Current Drug Targets
|July 24, 2004
Summary
Alzheimer's disease involves amyloid-beta peptide forming toxic structures. Beta-sheet breakers are a promising drug class designed to block this change, offering potential treatment for Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease (AD) pathogenesis is linked to amyloid-beta (Aβ) peptide misfolding into neurotoxic oligomers.
- These oligomers aggregate into insoluble amyloid deposits in the brain, contributing to AD pathology.
Purpose of the Study:
- To review the therapeutic strategy of using beta-sheet breakers for Alzheimer's disease.
- To discuss compounds targeting Aβ conformational changes and their potential as AD therapeutics.
Main Methods:
- Review of scientific literature on beta-sheet breakers and amyloid-beta peptide.
- Analysis of data supporting the efficacy of beta-sheet breaker compounds.
Main Results:
- Identified beta-sheet breakers as a novel drug class designed to inhibit Aβ aggregation.
- Summarized diverse compounds exhibiting beta-sheet breaking activity.
Conclusions:
- Beta-sheet breakers show potential in blocking or reversing pathological Aβ conformational changes.
- This class of drugs represents a promising therapeutic avenue for combating Alzheimer's disease.